ParkinsonCanadaV1, Main, Exploration, bibRecord, 002D59

The economic evaluation of pharmacotherapies for Parkinson's disease.

Identifieur interne : 002D59 ( Main/Exploration ); précédent : 002D58; suivant : 002D60

The economic evaluation of pharmacotherapies for Parkinson's disease.

Auteurs : D. Coyle [Canada] ; M. Barbeau ; M. Guttman ; J-F Baladi

Source :

Parkinsonism & related disorders [ 1353-8020 ] ; 2003.

RBID : pubmed:12781598

Descripteurs français

Wicri :
- geographic : Canada.

English descriptors

KwdEn :
- Antiparkinson Agents (economics), Antiparkinson Agents (therapeutic use), Canada, Catechols (economics), Catechols (therapeutic use), Cost-Benefit Analysis (methods), Drug Costs, Humans, Nitriles, Parkinson Disease (drug therapy), Parkinson Disease (economics).
MESH :
- chemical , economics : Antiparkinson Agents, Catechols.
- chemical , therapeutic use : Antiparkinson Agents, Catechols.
- geographic : Canada, Nitriles.
- drug therapy : Parkinson Disease.
- economics : Parkinson Disease.
- methods : Cost-Benefit Analysis.
- Drug Costs, Humans.

Abstract

As well as the significant clinical effects of Parkinson's disease (PD), the disease places a high economic burden on society. Given the scarcity of health care resources, it is becoming increasingly necessary to demonstrate that new therapies for PD provide value for money in comparison with other potential interventions. This paper outlines the basic techniques of cost-effectiveness analysis and its application to PD. These techniques are illustrated by a recent economic evaluation of entacapone for use in Canada.

PubMed: 12781598

Affiliations:

Canada

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The economic evaluation of pharmacotherapies for Parkinson's disease.</title>
<author><name sortKey="Coyle, D" sort="Coyle, D" uniqKey="Coyle D" first="D" last="Coyle">D. Coyle</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Ottawa Health Research Institute, Ottawa Hospital, University of Ottawa, 1053 Carling Avenue, Ottawa, Ont, Canada K1Y 4E9. dcoyle@ohri.ca</nlm:affiliation>
<country>Canada</country>
<wicri:regionArea>Department of Medicine, Ottawa Health Research Institute, Ottawa Hospital, University of Ottawa, 1053 Carling Avenue, Ottawa, Ont</wicri:regionArea>
<wicri:noRegion>Ont</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Barbeau, M" sort="Barbeau, M" uniqKey="Barbeau M" first="M" last="Barbeau">M. Barbeau</name>
</author>
<author><name sortKey="Guttman, M" sort="Guttman, M" uniqKey="Guttman M" first="M" last="Guttman">M. Guttman</name>
</author>
<author><name sortKey="Baladi, J F" sort="Baladi, J F" uniqKey="Baladi J" first="J-F" last="Baladi">J-F Baladi</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2003">2003</date>
<idno type="RBID">pubmed:12781598</idno>
<idno type="pmid">12781598</idno>
<idno type="wicri:Area/PubMed/Corpus">001434</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001434</idno>
<idno type="wicri:Area/PubMed/Curation">001434</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001434</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001434</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001434</idno>
<idno type="wicri:Area/Ncbi/Merge">000308</idno>
<idno type="wicri:Area/Ncbi/Curation">000308</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000308</idno>
<idno type="wicri:doubleKey">1353-8020:2003:Coyle D:the:economic:evaluation</idno>
<idno type="wicri:Area/Main/Merge">003134</idno>
<idno type="wicri:Area/Main/Curation">002D59</idno>
<idno type="wicri:Area/Main/Exploration">002D59</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The economic evaluation of pharmacotherapies for Parkinson's disease.</title>
<author><name sortKey="Coyle, D" sort="Coyle, D" uniqKey="Coyle D" first="D" last="Coyle">D. Coyle</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Ottawa Health Research Institute, Ottawa Hospital, University of Ottawa, 1053 Carling Avenue, Ottawa, Ont, Canada K1Y 4E9. dcoyle@ohri.ca</nlm:affiliation>
<country>Canada</country>
<wicri:regionArea>Department of Medicine, Ottawa Health Research Institute, Ottawa Hospital, University of Ottawa, 1053 Carling Avenue, Ottawa, Ont</wicri:regionArea>
<wicri:noRegion>Ont</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Barbeau, M" sort="Barbeau, M" uniqKey="Barbeau M" first="M" last="Barbeau">M. Barbeau</name>
</author>
<author><name sortKey="Guttman, M" sort="Guttman, M" uniqKey="Guttman M" first="M" last="Guttman">M. Guttman</name>
</author>
<author><name sortKey="Baladi, J F" sort="Baladi, J F" uniqKey="Baladi J" first="J-F" last="Baladi">J-F Baladi</name>
</author>
</analytic>
<series><title level="j">Parkinsonism & related disorders</title>
<idno type="ISSN">1353-8020</idno>
<imprint><date when="2003" type="published">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (economics)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Canada</term>
<term>Catechols (economics)</term>
<term>Catechols (therapeutic use)</term>
<term>Cost-Benefit Analysis (methods)</term>
<term>Drug Costs</term>
<term>Humans</term>
<term>Nitriles</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (economics)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Catechols</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Catechols</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Canada</term>
<term>Nitriles</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Cost-Benefit Analysis</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Costs</term>
<term>Humans</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">As well as the significant clinical effects of Parkinson's disease (PD), the disease places a high economic burden on society. Given the scarcity of health care resources, it is becoming increasingly necessary to demonstrate that new therapies for PD provide value for money in comparison with other potential interventions. This paper outlines the basic techniques of cost-effectiveness analysis and its application to PD. These techniques are illustrated by a recent economic evaluation of entacapone for use in Canada.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><noCountry><name sortKey="Baladi, J F" sort="Baladi, J F" uniqKey="Baladi J" first="J-F" last="Baladi">J-F Baladi</name>
<name sortKey="Barbeau, M" sort="Barbeau, M" uniqKey="Barbeau M" first="M" last="Barbeau">M. Barbeau</name>
<name sortKey="Guttman, M" sort="Guttman, M" uniqKey="Guttman M" first="M" last="Guttman">M. Guttman</name>
</noCountry>
<country name="Canada"><noRegion><name sortKey="Coyle, D" sort="Coyle, D" uniqKey="Coyle D" first="D" last="Coyle">D. Coyle</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D59 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002D59 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:12781598
   |texte=   The economic evaluation of pharmacotherapies for Parkinson's disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:12781598" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

The economic evaluation of pharmacotherapies for Parkinson's disease.

The economic evaluation of pharmacotherapies for Parkinson's disease.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.